Multiple Sclerosis (MS) Drug Market

Motley Fool  Feb 19  Comment 
A big phase 3 win for its up-and-coming multiple sclerosis drug could clear the path to billions of dollars in additional annual sales for this big-cap biotech stock.
DailyFinance  Feb 9  Comment 
Filed under: News, US, Weird News There are many appropriate responses to when someone is sharing a difficult situation his or her life. To congratulate that person is not one of them. Sen. Ted Cruz squared off against Sen. Bernie Sanders in a...
Reuters  Jan 18  Comment 
Mallinckrodt Plc has agreed to pay $100 million to settle allegations that a subsidiary broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug while ensuring that no rival medicine appeared on the market, the...
FierceBiotech  Jan 18  Comment 
Biogen, Siemens Healthineers to quantify MRI analysis for multiple sclerosis aalidrus Wed, 01/18/2017 - 11:24
Benzinga  Jan 11  Comment 
TG Therapeutics Inc (NASDAQ: TGTX) shares are trading higher by $0.03 at $5.03 in Wednesday's session. The issue was trading much higher earlier in the session following the announcement of positive Multiple Sclerosis study data. The news,...
NPR  Jan 8  Comment 
I like to eat, often and a lot. But when I heard about a medical study looking at whether fasting might tame the painful symptoms of MS, I was all in. Then I ate that 7 a.m. bagel.
Yahoo  Dec 22  Comment 
Teva Pharmaceutical Industries (TEVA.TA) agreed to pay more than $519 million to settle U.S. criminal and civil allegations that the company bribed overseas officials to gain business for its medications, the U.S. Department of Justice said on...
New York Times  Oct 31  Comment 
“President Bartlet will call on you at a press conference after he discloses he has multiple sclerosis,” my sister Dottie said over the phone in 2001. Huh?
Motley Fool  Oct 29  Comment 
The MS drug Goliath jumped into development of SP1 modulators last year, but a review of the competitive landscape resulted in a shuttering of the program this quarter, casting doubt on Biogen's future in the blockbuster indication.


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki